Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each patent provides Enlivex with added intellectual property (IP) protection in the United States until at least 2036 with respect to claims covering methods of treating sepsis with AllocetraTM.

Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

Nes-Ziona, Israel, April 29, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced its full year 2021 financial results, the completion of development of a frozen formulation of Allocetra™ twelve months ahead of schedule, and provided strategic updates on its clinical programs.

Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates

The stock price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) increased by over 4% during intraday trading today. This is why it happened.

Enlivex Therapeutics Stock (ENLV): Why The Price Increased Today

Publication follows the Israeli Ministry of Health's appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine

Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the Reuters Events' Cell & Gene Therapy USA 2021 event, which is taking place virtually on September 28 and 29, 2021.

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021

Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.

Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?

Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.

Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy

﻿Nes-Ziona, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the initiation of dosing in its multi-center, placebo-controlled, randomized, blinded, Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distress syndrome (ARDS).

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS

Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that Company management will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Does Enlivex Therapeutics Ltd. (ENLV) have what it takes to be a top stock pick for momentum investors?

Here's Why Enlivex Therapeutics Ltd. (ENLV) is a Great Momentum Stock to Buy

Enlivex Therapeutics Ltd  ( NASDAQ:ENLV) is surging today, up 21.8% at $12.39 at last check, after the drug maker said Israel's health ministry allowed it to kick off a mid-stage clinical trial to test its experimental therapy, Allocetra, in severe and critical Covid-19 patients with acute respiratory distress syndrome.

Enlivex Therapeutics Stock Surges on Covid-19 Therapy Update

The Israeli Ministry of Health has signed off Enlivex Therapeutics Ltd's (NASDAQ: ENLV) Phase 2b trial evaluating Allocetra in severe and critical COVID-19 patients with the acute respiratory distressed syndrome (ARDS). The Phase 2b trial will recruit up to 152 severe or critical COVID-19 patients in clinical centers in Israel and certain European countries.

Enlivex Therapeutics Stock Jumps On Initiation Of Another Mid-Stage COVID-19 Trial

The shares of Enlivex Therapeutics Ltd (NASDAQ: ENLV) increased by over 25% pre-market. This is why it happened.

Enlivex Therapeutics Shares Increase Over 25% Pre-Market: Why It Happened

Nes Ziona, Israel, Aug. 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today reported that after reviewing previously-reported Phase II trial data, the Israeli Ministry of Health has authorized the initiation of a proposed Company-sponsored, multi-center, placebo-controlled, randomized, blinded, Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distressed syndrome (ARDS).

Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

Nes Ziona, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that financial results for the second quarter ended June 30, 2021 were filed with the SEC on August 6, 2021 and provided a business update.

Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update

Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix Biotherapeutics, and as General Manager of ColBar LifeScience, a Johnson & Johnson company

Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant

Nes Ziona, Israel, July 14, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company will participate in, and present at, the ARDS Drug Development Summit on Thursday, July 15, 2021. During the presentation, which will take place at 3:30 p.m. ET, the Company will describe AllocetraTM's potential as a therapy for acute respiratory distress syndrome (ARDS) patients, who currently do not have effective treatment options. Those interested in registering for the summit can do so by visiting https://ards-summit.com.

Enlivex to Present at the ARDS Drug Development Summit 2021

Nes Ziona, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the Jefferies 2021 Virtual Healthcare Conference on June 4, 2021, 10:00 EDT. The presentation will be available through the conference website, at https://wsw.com/webcast/jeff174/enlv/1861731.

Enlivex to Present at the Jefferies 2021 Virtual Healthcare Conference

Grant provides $1.1 million in non-dilutive funding for 2021

Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company aiming to develop immunotherapies as mono/combination treatments based on macrophage reprogramming technology.

Enlivex: Interesting Macrophage Reprogramming Science Targets $33B Sepsis Market

Enlivex Therapeutics Ltd (NASDAQ: ENLV) and Yale Cancer Center announced a research collaboration to assess the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Allocetra is a macrophage-reprogramming immunotherapy product, a potential therapy combined with approved immune checkpoint inhibitors for hard-to-treat solid tumors.

Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor Settings

Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancers that do not respond to stand-alone checkpoint inhibitor therapies. Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancers that do not respond to stand-alone checkpoint inhibitor therapies.

Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors

Alteryx

Clorox

Kingsoft Cloud Holdings

Magnite

Rocket Companies, Inc.

Unity Software

These 7 risky stocks have solid fundamentals for long term growth. Use their drops now as an entry point into new highs.

Bet on Black With These 7 Risky Stocks

-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies -- Nes Ziona, Israel, March 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, and Mount Sinai Health System, one of the world's leading academic health systems, today announced a new research collaboration for the development of clinical strategies for Allocetra™ with checkpoint inhibitors.  Allocetra™ is a macrophage-reprogramming immunotherapy product candidate currently in clinical development by Enlivex for the potential treatment of life-threatening immune-mediated diseases.

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

Nes-Ziona, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,927,343 covering AllocetraTM, the company's immunotherapy product candidate.  The new patent is expected to provide added intellectual property protection for methods of treating autoimmune and inflammatory diseases comprising gout, inflammatory bowel disease, Crohn's disease, ulcerative colitis and graft versus host disease (GvHD).

Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy

News for Enlivex Therapeutics Ltd Stock (ENLV)